scholarly journals Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients

2013 ◽  
Vol 208 (2) ◽  
pp. 351-361 ◽  
Author(s):  
Lucy O'Connor ◽  
Joanne Livermore ◽  
Andrew D. Sharp ◽  
Joanne Goodwin ◽  
Lea Gregson ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients ◽  
Cryptococcal Meningoencephalitis

Liposomal amphotericin B for a case of intractable cryptococcal meningoencephalitis and immune reconstitution syndrome

2008 ◽  
Vol 55 (3,4) ◽  
pp. 292-296 ◽  
Author(s):  
Atsushi Sasakawa ◽  
Yoshihiko Yamamoto ◽  
Keishiro Yajima ◽  
Mio Sakai ◽  
Tomoko Uehira ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Immune Reconstitution ◽  
Liposomal Amphotericin B ◽  
Immune Reconstitution Syndrome ◽  
Cryptococcal Meningoencephalitis

scholarly journals Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis

2017 ◽  
Vol 61 (6) ◽  
Author(s):  
Jodi Lestner ◽  
Laura McEntee ◽  
Adam Johnson ◽  
Joanne Livermore ◽  
Sarah Whalley ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Induction Therapy ◽  
Liposomal Amphotericin ◽  
Experimental Models ◽  
Liposomal Amphotericin B ◽  
Perivascular Spaces ◽  
Histopathological Changes ◽  
Time Curve ◽  
Cryptococcal Meningoencephalitis ◽  
The Brain

ABSTRACT Cryptococcal meningoencephalitis is a rapidly lethal infection in immunocompromised patients. Induction regimens are usually administered for 2 weeks. The shortest effective period of induction therapy with liposomal amphotericin B (LAMB) is unknown. The pharmacodynamics of LAMB were studied in murine and rabbit models of cryptococcal meningoencephalitis. The concentrations of LAMB in the plasma and brains of mice were measured using high-performance liquid chromatography (HPLC). Histopathological changes were determined. The penetration of LAMB into the brain was determined by immunohistochemistry using an antibody directed to amphotericin B. A dose-dependent decline in fungal burden was observed in the brains of mice, with near-maximal efficacy achieved with LAMB at 10 to 20 mg/kg/day. The terminal elimination half-life in the brain was 133 h. The pharmacodynamics of a single dose of 20 mg/kg was the same as that of 20 mg/kg/day administered for 2 weeks. Changes in quantitative counts were reflected by histopathological changes in the brain. Three doses of LAMB at 5 mg/kg/day in rabbits were required to achieve fungicidal activity in cerebrospinal fluid (cumulative area under the concentration-time curve, 2,500 mg · h/liter). Amphotericin B was visible in the intra- and perivascular spaces, the leptomeninges, and the choroid plexus. The prolonged mean residence time of amphotericin B in the brain suggests that abbreviated induction regimens of LAMB are possible for cryptococcal meningoencephalitis.

scholarly journals Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis

2013 ◽  
Vol 57 (7) ◽  
pp. 3340-3347 ◽  
Author(s):  
Guanpingsheng Luo ◽  
Teclegiorgis Gebremariam ◽  
Hongkyu Lee ◽  
Samuel W. French ◽  
Nathan P. Wiederhold ◽  
...  
Keyword(s):  
Fungal Infection ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Intratracheal Instillation ◽  
Cortisone Acetate ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients ◽  
Content Type ◽  
Pulmonary Mucormycosis ◽  
Life Threatening

ABSTRACTMucormycosis is a life-threatening fungal infection almost uniformly affecting diabetics in ketoacidosis or other forms of acidosis and/or immunocompromised patients. Inhalation ofMucoralesspores provides the most common natural route of entry into the host. In this study, we developed an intratracheal instillation model of pulmonary mucormycosis that hematogenously disseminates into other organs using diabetic ketoacidotic (DKA) or cyclophosphamide-cortisone acetate-treated mice. Various degrees of lethality were achieved for the DKA or cyclophosphamide-cortisone acetate-treated mice when infected with different clinical isolates ofMucorales. In both DKA and cyclophosphamide-cortisone acetate models, liposomal amphotericin B (LAmB) or posaconazole (POS) treatments were effective in improving survival, reducing lungs and brain fungal burdens, and histologically resolving the infection compared with placebo. These models can be used to study mechanisms of infection, develop immunotherapeutic strategies, and evaluate drug efficacies against life-threateningMucoralesinfections.

Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients

2010 ◽  
Vol 12 (5) ◽  
pp. 428-431 ◽  
Author(s):  
E. Vigna ◽  
A. De Vivo ◽  
M. Gentile ◽  
R. Morelli ◽  
E. Lucia ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients

Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients

2013 ◽  
Vol 49 (6) ◽  
pp. 574-580 ◽  
Author(s):  
Harutai Kamalaporn ◽  
Kitty Leung ◽  
Mark Nagel ◽  
Saranya Kittanakom ◽  
Battista Calvieri ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Invasive Pulmonary Aspergillosis ◽  
Liposomal Amphotericin B ◽  
Immunocompromised Patients ◽  
Pulmonary Aspergillosis

Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study

2008 ◽  
Vol 31 (2) ◽  
pp. 135-141 ◽  
Author(s):  
Catherine Cordonnier ◽  
Mohamad Mohty ◽  
Catherine Faucher ◽  
Cécile Pautas ◽  
Marie Robin ◽  
...  
Keyword(s):  
Fungal Infection ◽  
Amphotericin B ◽  
Invasive Fungal Infection ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
High Dose ◽  
Immunocompromised Patients
Sign in / Sign up

Export Citation Format

Share Document